Johnson & Johnson (JNJ.N)
86.63USD
1 Jul 2013
$0.77 (+0.90%)
$85.86
$85.61
$87.63
$85.61
2,622,347
2,711,243
$89.99
$66.86
JNJ.N
About
Overall
| Beta: | 0.57 |
| Market Cap (Mil.): | $243,333.91 |
| Shares Outstanding (Mil.): | 2,808.89 |
| Dividend: | 0.66 |
| Yield (%): | 3.05 |
Financials
| JNJ.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 23.56 | 32.01 | 33.02 |
| EPS (TTM): | 3.68 | -- | -- |
| ROI: | 10.41 | 19.61 | 19.07 |
| ROE: | 16.28 | 20.45 | 20.00 |
J&J in $1 billion deal to bolster prostate-cancer focus
- Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.
UPDATE 2-J&J in $1 bln deal to bolster prostate-cancer focus
By Ransdell Pierson June 17 - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand. J&J on Monday said Aragon's lead product, called ARN-509, has potential to help patients whose prostate cancer has not yet spread to other parts of the body, as well as patient
Johnson & Johnson to buy Aragon for up to $1 billion
June 17 - Johnson & Johnson said on Monday that it would buy Aragon Pharmaceuticals, a private company that is running a mid-stage clinical trial for a prostate cancer drug, for $650 million in cash upfront and a possible second payment of $350 million if it meets certain milestones.
J&J's Stelara effective in psoriatic arthritis trial
June 11 - Johnson & Johnson's Stelara produced significant improvement in signs and symptoms of psoriatic arthritis through 52 weeks of treatment in a late stage study, according to data being presented at a medical meeting in Europe.
Johnson & Johnson recalls Cilest birth control pills
- Johnson & Johnson is voluntarily recalling about 32 million packages of its birth control pill Cilest in Europe, Asia and Latin America, a spokeswoman said late on Tuesday, the latest in a string of recalls over the past two years.
Johnson & Johnson recalls Cilest birth control pills
June 5 - Johnson & Johnson is voluntarily recalling about 32 million packages of its birth control pill Cilest in Europe, Asia and Latin America, a spokeswoman said late on Tuesday, the latest in a string of recalls over the past two years.
New J&J anti-depressant related to 'Special K' party drug
NEW BRUNSWICK, New Jersey - Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients with depression who have failed to benefit from standard medications.
UPDATE 4-New J&J anti-depressant related to 'Special K' party drug
NEW BRUNSWICK, N.J., May 23 - Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients with depression who have failed to benefit from standard medications.
Johnson & Johnson plans on more than 10 drugs filed by 2017
May 23 - Johnson & Johnson said on Thursday that it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases, and schizophrenia as well as vaccines for flu, rabies and polio.
FDA approves J&J's Simponi to treat ulcerative colitis
- The Food and Drug Administration has approved Johnson & Johnson's drug Simponi for patients with moderate to severe ulcerative colitis, an inflammatory disease affecting the colon.
Competitors
| Price | Change | |
|---|---|---|
| General Electric Company (GE.N) | $23.34 | +0.15 |
| The Procter & Gamble Company (PG.N) | $78.02 | +1.03 |
| Pfizer Inc. (PFE.N) | $27.78 | -0.23 |
| Novartis AG (NOVN.VX) | CHF67.05 | -0.25 |
| Merck & Co., Inc. (MRK.N) | $46.32 | -0.13 |
| Medtronic, Inc. (MDT.N) | $52.05 | +0.58 |
| Baxter International Inc. (BAX.N) | $70.06 | +0.79 |
| Stryker Corporation (SYK.N) | $64.43 | -0.25 |
| Boston Scientific Corporation (BSX.N) | $9.37 | +0.10 |
| Zimmer Holdings, Inc. (ZMH.N) | $75.00 | +0.06 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (JNJ). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
